CONFERENCE PROGRAMME
2007 NCRI Cancer Conference, 30 September - 3 October 2007, The ICC, Birmingham, UK
Programme Contents

Programme at a Glance

Symposia
For the first time, the Conference features a number of symposia on subjects of broad appeal, including: 25 years of Ras; Clinical trials in an environment of new agents; and Biomarkers for cancer predisposition screening and prognosis.

Parallel Sessions
This year’s sessions cover a breadth of topics, based on the central themes of cancer cell biology, clinical research, enabling infrastructure and resources, epidemiology and prevention, patients and the public, supportive and palliative care, and therapeutic development.

Workshops
The Conference also features workshops designed for specialists involved in cancer research, addressing subjects such as careers and development, clinical trial design, and issues affecting women in science.
Programme at a Glance

Sunday 30 September 2007


13.00 – 15.00  Workshops

14.00 – 15.00  Drug hunting to beat cancer: Public Seminar and Open Forum
   Roger Griffin
   Northern Institute for Cancer Research, Newcastle University, UK

15.15 – 15.30  Welcome address
   Mike Richards
   NCRI Chairman

15.30 – 16.10  Mouse models for cancer - The Beatson Institute for Cancer Research Lecture
   Anton Berns
   Netherlands Cancer Institute, The Netherlands

16.10 – 16.50  Promoting early presentation with cancer - The Economic and Social Research Council Lecture
   Amanda Ramirez
   King’s College London, UK

16.50 – 17.20  Refreshment Break

17.20 – 18.00  Sensing of infection and anti-tumour immunity – The AstraZeneca Lecture
   Caetano Reis e Sousa
   CR-UK London Research Institute, UK

18.00 – 18.40  Targeting epigenetic alterations in breast cancer - The CR-UK Cambridge Research Institute Lecture
   Nancy Davidson
   Johns Hopkins University School of Medicine, Baltimore, USA
19.00 – 21:00 Civic Opening Reception and Trade Exhibition

Monday 1 October 2007

08.00 – 08.50 Educational Workshops

09.00 – 09.10 Introduction to the programme
      Alan Ashworth
      Programme Planning Committee Chairman

09.10 – 09.50 Drugging the ‘undruggable’ - The CR-UK London Research Institute Lecture
      Gregory Verdine
      Harvard University, Cambridge, USA

09.50 – 10.30 Immunological checkpoint blockade in cancer therapy – The Leukaemia Research Fund Lecture
      James Allison
      Memorial Sloan-Kettering Cancer Center, New York, USA

10.30 – 11.00 Refreshment Break and Exhibition Viewing

11.00 – 12.30 Symposia

12.30 – 15.00 Lunch, Poster Session 1 and Trade Exhibition

13.00 – 14.00 Commercial Workshops

14.00 – 15.00 Workshops

15.15 – 17.30 Parallel Sessions

17.30 – 18.00 Refreshment Break

18.00 – 19.00 Clinical Trials Showcase

19.20 – 21.00 Drinks Reception

19.20 – 20.30 Sponsors’ Reception (by invitation only)

20.30 – 23.00 Chairman’s Dinner (by invitation only)
Tuesday 2 October 2007

08.00 – 08.50  Educational workshops

09.00 – 09.40  **Pancreatic cancer models and medicine – The Cancer Research UK Lecture**
                **David Tuveson**
                CR-UK Cambridge Research Institute, UK

09.40 – 10.20  **Living beyond cancer: the challenges of survivorship care – The Cancer Research UK Lecture**
                **Mary McCabe**
                Memorial Sloan-Kettering Cancer Center, New York, USA

10.20 – 11.00  Refreshment Break and Exhibition Viewing

11.00 – 12.30  Symposia

12.30 – 15.00  Lunch, Poster Session 2 and Trade Exhibition

13.00 – 14.00  Commercial Workshops

14.00 – 15.00  Workshops

15.15 – 17.30  Parallel Sessions

17.30 – 18.00  Refreshment Break

18.00 – 18.40  **Nutritional and molecular markers in cancer prevention - The Medical Research Council Lecture**
                **Sheila Bingham**
                MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, University of Cambridge, UK

18.40 – 19.20  **Using cancer genomics to inform targeted drug development - The Medical Research Council Lecture**
20.00 – 20.30  Drinks Reception
20.30 – 02.00  Conference Dinner and Party

Wednesday 3 October

09.00 – 11.15  Parallel Sessions
11.15 – 11.45  Refreshment Break
11.45 – 12.25  Future prospects for targeted therapies - The BACR Tom Connors Lecture
Frank McCormick
University of California, Comprehensive Cancer Center, San Francisco, USA

12.25 – 12.35  Closing Comments
Mike Richards
NCRI Chairman

12.35 – 13.30  Lunch Boxes
13.00 – 17.30  Commercial Workshop
Symposia

Monday 1 October 2007

**25 years of Ras – Sponsored by The Institute of Cancer Research**
Hosted by Chris Marshall
The Institute of Cancer Research, London, UK

- **Chris Marshall**
  The Institute of Cancer Research, London, UK
  **Introduction: Ras oncogenes - what next?**

- **John Hancock**
  Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
  **Spatiotemporal control of Ras plasma membrane signalling**

- **Judith Sebolt-Leopold**
  JS Leopold Consulting, Michigan, USA
  **MEK inhibitors: a personalised medicine approach for targeting aberrant MAP kinase signalling**

- **Julian Downward**
  CR-UK London Research Institute, UK
  **The Ras oncogene signalling network in cancer**

**Clinical trials in an environment of new agents - Sponsored by the Paterson Institute for Cancer Research and the Manchester Cancer Research Centre**
Hosted by Stan Kaye
The Institute of Cancer Research and Royal Marsden Hospital, London, UK

- **Stan Kaye**
  The Institute of Cancer Research and Royal Marsden Hospital, London, UK
  **Introduction: novel agents for treating cancer; how has the landscape changed?**

- **Mitch Dowsett**
  The Institute of Cancer Research and Royal Marsden Hospital, London, UK
  **Opportunities and limitations of short-term clinico-biological studies**

- **Jaap Verweij**
  Erasmus University Medical Center, Rotterdam, The Netherlands
  **How to assess response – changing concepts about endpoints**

- **Mark Ratain**
  Cancer Research Center, University of Chicago, USA
  **How to assess response – is randomisation necessary?**
Complementary therapies
Hosted by Andrew Ritchie
Papworth Hospital, Cambridge, UK
- Andrew Ritchie
  Papworth Hospital, Cambridge, UK
  Introduction
- Edzard Ernst
  Peninsula Medical School, Exeter, UK
  CAM for cancer: the good, the bad and the ugly
- George Lewith
  Peninsula Medical School, Exeter, UK
  CAM and cancer: what do we know and how do we move forward?
- Donald Sharp
  Institute of Rehabilitation, University of Hull, UK
  Prevention – the impact of lifestyle factors

Tuesday 2 October 2007

Biomarkers for cancer predisposition, screening and prognosis – Sponsored by Illumina
Hosted by Herbie Newell
Northern Institute for Cancer Research, Newcastle University, UK
- Herbie Newell
  Northern Institute for Cancer Research, Newcastle University, UK
  Introduction: predisposition, screening and prognostic biomarkers in cancer management
- Paul Pharoah
  Strangeways Research Laboratory, University of Cambridge, UK
  Genome-wide association studies for common cancer-predisposing genes
- Fritz Schröder
  Erasmus Medical Centre, Rotterdam, The Netherlands
  Early detection of prostate cancer in 2007
- Ian Smith
  The Institute of Cancer Research and Royal Marsden Hospital, London, UK
  Prognostic and predictive biomarkers in early breast cancer

Chromatin regulation and cancer
Hosted by Tony Kouzarides
The Wellcome Trust/CR-UK Gurdon Institute, University of Cambridge, UK
- Tony Kouzarides
  Wellcome Trust/CR-UK Gurdon Institute, University of Cambridge, UK
  Introduction: chromatin modifications, pathways and cancer
- Steve Baylin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA
The gene silencing component of the cancer epigenome
- Kristian Helin
  Biotech Research and Innovation Centre, University of Copenhagen, Denmark
  Epigenetic control and the development of cancer
- Manel Esteller
  Spanish National Cancer Centre, Madrid, Spain
  DNA methylation and cancer
- Pier Giuseppe Pelicci
  European Institute of Oncology, Milan, Italy
  Higher-order chromatin changes induced by an oncogenic transcription factor

Prevention
Hosted by William Steward
Leicester Royal Infirmary, University of Leicester, UK
- William Steward
  Leicester Royal Infirmary, University of Leicester, UK
  Introduction: cancer prevention strategies – importance for the future management of the burden of cancer in society
- Julian Peto
  The Institute of Cancer Research and the London School of Hygiene and Tropical Medicine, UK
  Prevention – the impact of lifestyle factors
- Andrea Decensi
  Ente Ospedaliero Ospedali Galliera, Genoa, Italy
  Clinical chemoprevention: where do we stand?
- Andreas Gescher
  University of Leicester, UK
  Cancer prevention – the way ahead
Parallel Sessions

Monday 1 October 2007

**Angiogenesis - Sponsored by Astrazeneca**
Hosted by Roy Bicknell
Institute for Biomedical Research, University of Birmingham, UK

- **Roy Bicknell**
  Institute for Biomedical Research, University of Birmingham, UK
  Introduction: Robo4 in endothelial biology and angiogenesis

- **Holger Gerhardt**
  CR-UK London Research Institute, UK
  Regulating sprouting angiogenesis

- **Andreas Bikfalvi**
  Inserm, University of Bordeaux I, Talence, France
  New insights into the regulation of tumour angiogenesis: mechanisms, models and molecules

- **Stephen Wedge**
  AstraZeneca, Macclesfield, UK
  Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors: potential and recent clinical progress

- **Richard Sainson**
  University of Oxford, UK
  *In vivo* assessment of Delta like-4 function in tumour development – Proffered Paper Presentation

- **Francois Pepin**
  McGill University, Montreal, Quebec, Canada
  Identification and characterisation of classes of endothelial gene expression in breast cancer – Proffered Paper Presentation

- **Russell Hughes**
  University of Sheffield Tumour Targeting Group, South Yorkshire, UK
  Use of a transgenic zebrafish embryo to investigate the anti-angiogenic and anti-vascular effects of a novel pentapeptide derived from human fibronectin – Proffered Paper Presentation

**Breast cancer stem cells and detection of minimal residual disease – Sponsored by GlaxoSmithKline**
Hosted by Rob Coleman
Weston Park Hospital, University of Sheffield, UK

- **Rob Coleman**
  Weston Park Hospital, University of Sheffield, UK
  Introduction: how can we rationalise the treatment of micrometastatic disease?

- **Robert Clarke**
  Department of Medical Oncology, University of Manchester, UK
Regulation of human breast cancer stem cells
- **Sabine Riethdorf**  
  Institute for Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany  
  Detection and characterisation of circulating tumour cells in blood and micrometastasis in bone marrow

- **Charles Coombes**  
  Hammersmith Hospital, London, UK  
  Minimal residual disease in patients with primary breast cancer: role in monitoring patients

- **Paul Symonds**  
  University of Leicester, UK  
  The late radiotherapy normal tissue phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependant causes – Proffered Paper Presentation

- **Andrew Green**  
  University of Nottingham, UK  
  Identification of breast cancer sub-classes by consensus derived from automated clustering methods – Proffered Paper Presentation

- **Heiko Enderling**  
  Tufts University, Boston, USA  
  A mathematical model of breast cancer development, local treatment and recurrence – Proffered Paper Presentation

---

**Cancer epidemiology**
**Hosted by Peter Sasieni**  
Wolfson Institute of Preventive Medicine, Queen Mary’s School of Medicine and Dentistry, UK

- **Peter Sasieni**  
  Wolfson Institute of Preventive Medicine, Queen Mary’s School of Medicine and Dentistry, UK  
  Introduction

- **Gad Rennert**  
  Carmel Medical Center and B Rappaport Faculty of Medicine, Technion, Israel  
  Colorectal cancer prevention: health habits, use of medications and genes

- **Maxwell Parkin**  
  University of Oxford, UK  
  Epidemiology of breast cancer: how much can we prevent?

- **Rowan Chlebowski**  
  Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, California, USA  
  The Women’s Health Initiative randomised trials of menopausal hormone therapy

- **Tim Key**  
  University of Oxford, UK  
  Diet, hormones and prostate cancer: findings in the EPIC study – Proffered Paper Presentation
Colorectal cancer - Sponsored by The Bobby Moore Fund
Hosted by John Northover
St Mark's Hospital, Middlesex, UK

- **John Northover**
  St Mark's Hospital, Middlesex, UK
  Introduction

- **Wendy Atkin**
  St Mark's Hospital, Imperial College London, UK
  NHS population screening: possible developments in the next five years

- **Paul Finan**
  Leeds General Infirmary, UK
  Abdominoperineal excision of rectum (APER) - a suitable case for treatment

- **Tom Treasure**
  Guy's Hospital, London, UK
  Pulmonary metastasectomy: its role should be better defined

- **Helen Thorpe**
  University of Leeds, UK
  CLASICC Trial (Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer): 5-year survival results – Proffered Paper Presentation

- **S Paneesha**
  Heart of England NHS Trust, Birmingham, UK
  Venous thrombosis has an adverse impact on the survival in patients with malignancy – Proffered Paper Presentation

- **Trevor McGoldrick**
  University of Edinburgh, Scotland, UK
  National survey of fluoropyrimidine induced cardiac ischaemia – Proffered Paper Presentation

Molecular pathology - Sponsored by the Pathological Society of Great Britain and Ireland
Hosted by Nick Lemoine
Institute of Cancer and CR-UK Clinical Centre, University of London, UK

- **Nick Lemoine**
  Institute of Cancer and CR-UK Clinical Centre, University of London, UK
Introduction: what do we need to qualify biomarkers in molecular pathology?

- **Paul Waring**
  Genentech, San Francisco, USA
  The importance of selecting the right patients for the right drugs

- **Heike Grabsch**
  University of Leeds, UK
  Molecular profiling of gastrointestinal malignancies for targeted therapy

- **Nils Brunner**
  Copenhagen University Hospital, Denmark
  Cancer biomarkers in a European perspective

- **Emma Dean**
  Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
  Cell death ELISAs in the clinical evaluation of AEG35156 (XIAP Antisense): a multifaceted biomarker? – Proffered Paper Presentation

- **Muireann Kelleher**
  Randall Division and Cancer Studies, King’s College London, UK
  High throughput optical proteomics and breast cancer patient profiling; novel applications to individualise prognosis and treatment – Proffered Paper Presentation

- **Loreta Rodrigues**
  CR-UK Cambridge Research Institute, UK
  Pharmacodynamic markers in C-neu/HER2 overexpressing mammary carcinomas in response to 17-AAG measured by $^{31}$P magnetic resonance spectroscopy – Proffered Paper Presentation

**Signalling pathways**

*Hosted by Xin Lu*
Ludwig Institute for Cancer Research, UK

- **Xin Lu**
  Ludwig Institute for Cancer Research, UK
  Introduction

- **Carl-Henrik Heldin**
  Ludwig Institute for Cancer Research, Uppsala University, Sweden
  Signal transduction via receptors for PDGF and TGF-β: possible targets in tumour therapy

- **George D Demetri**
  Dana-Farber Cancer Institute, Boston, USA
  Molecular therapeutics targeting aberrant kinase signalling in gastrointestinal stromal tumours (GIST): lessons for rational drug design and pathway-focused clinical development

- **Stefan Constantinescu**
  Ludwig Institute for Cancer Research, Brussels, Belgium
  Signalling by JAK2 V617F and thrombopoietin receptor mutants in human myeloproliferative diseases
- Surbhi Gupta
  CR-UK London Research Institute, UK
  The interaction of Ras with p110α is required for Ras-driven tumorigenesis and for normal lymphatic development – Proffered Paper Presentation

- Adrian Saurin
  CR-UK London Research Institute, UK
  The regulated assembly of a PKC epsilon complex controls the completion of cytokinesis – Proffered Paper Presentation

- Ivana Samarzija
  Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
  Studies on Memo, a novel ERBB2 effector protein – Proffered Paper Presentation

**Survival strategies and clinical trials**
Hosted by Roger Wilson
NCRI Consumer Liaison Group, UK

- Roger Wilson
  NCRI Consumer Liaison Group, UK
  Introduction

- Jan Geissler
  European Cancer Patient Coalition, Germany
  Cancer trials as live savers: a patient’s perspective on public trial information

- Ian Judson
  Royal Marsden Hospital, London, UK
  Early clinical trials in cancer – human toxicology studies or realistic hope of benefit?

- Derryn Borley
  Cancerbackup, UK
  The role of patient support and information services

- Donald Sharp
  University of Hull, UK
  Integrated psychosocial support services for people with cancer enhance equity of use – Proffered Paper Presentation

**Symptom management**
Hosted by Michael Sharpe
Edinburgh Cancer Research Centre, University of Edinburgh, UK

- Michael Sharpe
  Edinburgh Cancer Research Centre, University of Edinburgh, UK
  Introduction: improving the management of symptoms in people with cancer - trials and tribulations

- Michael Sharpe
  Edinburgh Cancer Research Centre, University of Edinburgh, UK
  A randomised trial of a multi-component intervention for major depressive disorder in cancer patients

- Gijs Bleijenberg
A randomised trial of cognitive behaviour therapy for fatigue in cancer survivors

Matthew Hotopf
Institute of Psychiatry, Weston Education Centre, London, UK
Integrating principles of cognitive behavioural therapy in palliative care: a cluster randomised trial of nurse training

Jo Armes
King’s College London, UK
A randomised controlled trial to evaluate the effectiveness of a brief behaviourally oriented intervention for cancer-related fatigue – Proffered Paper Presentation

Moyra Mills
Queen's University Belfast, Northern Ireland, UK
A randomised controlled trial of a patient-held quality of life diary for patients with inoperable lung cancer – Proffered Paper Presentation

Galina Velikova
Cancer Research UK Centre, Leeds, UK
Patients’ and doctors’ attitude to the routine use of quality of life assessment in oncology practice – Proffered Paper Presentation

Tuesday 2 October 2007

Biobanking
Hosted by Gerry Thomas
Hammersmith Hospital, London, and Wales Cancer Bank, Cardiff, UK

Gerry Thomas
Hammersmith Hospital, London, and Wales Cancer Bank, Cardiff, UK
Introduction

Lisa Devereux
Peter MacCallum Cancer Centre, Melbourne, Australia
The Australasian Biospecimen Network (ABN): progress so far. A tale of linkage, supply and co-operation

Fay Betsou
Responsable Laboratoire, Saleux, France
Biobanks in France and the Biobanque de Picardie paradigm

Chris Womack
AstraZeneca, UK
What industry wants from cancer research tissue banks – ethics, quality and data

Susan Bray
University of Dundee, Scotland, UK
Colorectal cancer gene expression profiles are dependent upon tissue ischaemic time and tissue handling protocols – Proffered Paper Presentation
o **Gavin Whyman**  
Children's Cancer and Leukaemia Group, University of Leicester, UK  
The childhood tumour and leukaemia banks - A national protocol for collecting and banking childhood cancer tissue samples for research – Proffered Paper Presentation

o **Rebecca Elliott**  
University of Manchester, UK  
VORTEX-BIOBANK: Translational tissue banking study – Proffered Paper Presentation

---

**Cervical cancer vaccines - Sponsored by Merck Sharp & Dohme**  
Hosted by Henry Kitchener  
University of Manchester, UK

---

o **Henry Kitchener**  
University of Manchester, UK  
Introduction: the role of prophylactic human papillomavirus vaccination

o **Richard Roden**  
Johns Hopkins School of Medicine, Baltimore, USA  
Second generation human papillomavirus vaccines based on L2

o **Cornelius Melief**  
Leiden University Medical Centre, The Netherlands  
Long peptide vaccine-induced migration of HPV16 specific type 1 and 2 T cells into the lesions of VIN III patients, associated with complete clinical responses

o **Loretta Brabin**  
University of Manchester, UK  
Human papillomavirus vaccine implementation issues

o **Neil Steven**  
University of Birmingham, UK  
Vaccination of patients with Epstein-Barr virus positive malignancy with modified Vaccinia Ankara expressing a chimaeric EBV EBNA 1 and LMP2 antigen – Proffered Paper Presentation

o **Robin Prestwich**  
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds, UK  
Reovirus infection of human melanoma cells supports priming of anti-tumour cytotoxic T cell immunity – Proffered Paper Presentation

o **Robin Prestwich**  
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds, UK  
Clinical study of intralymphatic delivery of OK432-matured dendritic cells for activation of innate anti-tumour immunity – Proffered Paper Presentation
Exercise, the mind and curative intent
Hosted by Nina Ennis
NCRI Consumer Liaison Group, UK

- Nina Ennis
  NCRI Consumer Liaison Group, UK
  Introduction

- Donald Sharp
  Institute of Rehabilitation, University of Hull, UK
  Integrating the researcher, the clinician and the patient in psycho-oncology research: pleasing all of the people all of the time?

- Amanda Daley
  University of Birmingham, UK
  Rest is not best: exercise therapy and quality of life in women treated for breast cancer

- Francis Creed
  School of Medicine, University of Manchester, UK
  Can a brief psychological intervention prevent affective disorders in cancer patients? A randomised controlled trial

- Susan Palmer
  Thames Valley Cancer Research Network, Oxford, UK
  Does increasing research awareness impact on accrual? A feasibility study (NCRN Portfolio: RAW study) – Proffered Paper Presentation

High-throughput siRNA screening
Hosted by Julian Downward
CR-UK London Research Institute, UK

- Julian Downward
  CR-UK London Research Institute, UK
  Introduction: high throughput RNA interference in the analysis of signalling pathways involved in oncogenic transformation

- Michael White
  University of Texas Southwestern Medical Center, Dallas, USA
  Harnessing genome-wide RNAi to guide rational design of combinatorial chemotherapies

- Christoph Sachse
  Cenix BioScience GmbH, Dresden, Germany
  Combining high throughput RNAi with high content assays to advance anti-cancer drug discovery and development

- Andrew Fraser
  Wellcome Trust Sanger Institute, Cambridge, UK
  Learning from the worm: predicting phenotype from genotype

- Lindsay Stimson
  University of Oxford, UK
  Genome-wide loss-of-function screen reveals an unexpected mechanism for HDAC-inhibitor-induced apoptosis – Proffered Paper Presentation

- Michael Steckel
Integration of new molecular therapies with radiation – 
Sponsored by The Royal College of Radiologists and The British Oncological Association
Hosted by Chris Nutting and Frances Calman
Royal Marsden Hospital, London, UK and The Royal College of Radiologists, London, UK

- **Chris Nutting and Frances Calman**
  Royal Marsden Hospital, London, UK and The Royal College of Radiologists, London, UK
  Introduction

- **Chris Boshoff**
  Wolfson Institute for Biomedical Research, University College London, UK
  Novel molecular targets and molecules in cancer therapy

- **Suresh Senan**
  VU University Medical Center, Amsterdam, The Netherlands
  Epidermal growth factor modulation and vascular targeted agents combined with radiation therapy: early lessons from clinical trials

- **Kevin Harrington**
  The Institute of Cancer Research, London, UK
  Biological approaches to radiosensitisation: viruses, gene therapy and novel radiosensitisers

- **Fadhel Shaheen**
  Northern Institute for Cancer Research, Newcastle Upon Tyne, UK
  Targeting the DNA repair machinery to develop novel therapies for prostate cancer – Proffered Paper Presentation

- **Judith Anderton**
  AstraZeneca, Macclesfield, United Kingdom
  Preclinical studies comparing the pharmacological profiles of the EGFR tyrosine kinase inhibitors gefitinib (IRESSA™) and erlotinib (Tarceva™) – Proffered Paper Presentation

- **Samra Khan**
  Northern Institute of Cancer Research, Newcastle upon Tyne, UK
  DNA damage and repair in BRCA2 heterozygotes in response to ionising radiation and PARP inhibitors – Proffered Paper Presentation

Living with cancer as a chronic illness
Hosted by Karen Luker
School of Nursing, University of Manchester, UK

- **Karen Luker**
  School of Nursing, University of Manchester, UK
  Introduction

- **Noreen Aziz**
Division of Cancer Control and Population Sciences,
National Cancer Institute, USA
Cancer as a chronic illness: overcoming adverse sequelae to achieve an optimal new normal
- **Gerry Humphris**
  University of St Andrews, Fife, Scotland, UK
  Concerns for the future: cancer survivors’ psychological trajectory following treatment
- **Carol Tishelman**
  Karolinska Institute and Stockholms Sjukhem Foundation, Stockholm, Sweden
  Living with cancer as a chronic disease: accommodating user perspectives and priorities to better alleviate problems and support strengths
- **Nada Khan**
  University of Oxford, UK
  Long-term cancer survivors in primary care: a systematic review of uptake of services and support needs – Proffered Paper Presentation
- **Judith Mills**
  The Institute of Cancer Research, Sutton, UK
  Return to paid and unpaid activities after radiotherapy for early stage breast cancer – Proffered Paper Presentation
- **Claire Foster**
  University of Southampton, UK
  Psychosocial implications of long term survival following a cancer diagnosis – Proffered Paper Presentation

**Paediatric cancers – Organised by the Children’s Cancer and Leukaemia Group, sponsored by Children with Leukaemia**
Hosted by Sue Burchill
CR-UK Clinical Centre, St James’s University Hospital, Leeds, UK
- **Sue Burchill**
  CR-UK Clinical Centre, St James's University Hospital, Leeds, UK
  Introduction: challenges for the implementation of biomarker-based targeted therapy
- **Julia Glade Bender**
  Children's Hospital of New York-Presbyterian, Columbia University, USA
  The development of VEGF targeted therapies in paediatric solid tumours
- **Vaskar Saha**
  University of Manchester, UK
  Novel therapeutic targets in childhood acute lymphoblastic leukaemia
- **Caroline Dive**
  Paterson Institute for Cancer Research, University of Manchester, UK
  Targeting death pathways for therapeutic advantage in childhood malignancy
- **Guy Makin**
Pre-clinical evaluation of the novel alkylating agent RH1 against paediatric tumour cell lines – Proffered Paper Presentation

- **Tapiwanashe Magwere**
  University of Leeds, UK
  Cellular glutathione modulates ESFT sensitivity to fenretinide-induced cell death – Proffered Paper Presentation

- **Sarah Holt**
  Paterson Institute for Cancer Research, Manchester, UK
  A novel XIAP antisense oligonucleotide induces apoptosis and sensitises paediatric tumour cells to cytotoxics – Proffered Paper Presentation

### Structural biology

**Hosted by Yvonne Jones**
Wellcome Trust Centre for Human Genetics, Oxford, UK

- **Yvonne Jones**
  Wellcome Trust Centre for Human Genetics, Oxford, UK
  Introduction

- **David Barford**
  The Institute of Cancer Research, London, UK
  Structural and functional studies of argonaute proteins

- **Sir Alan Fersht**
  MRC Centre for Protein Engineering, University of Cambridge, UK
  The tumour suppressor p53: structure, function - rescue

- **Daan van Aalten**
  University of Dundee, UK
  Structural dissection of the LKB1 tumour suppressor complex

- **Brenda Kostelecky**
  CR–UK London Research Institute, UK
  PKC regulation and specificity: a study of novel isoforms – Proffered Paper Presentation

- **Heide Kogelberg**
  Royal Free and University College Medical School, London, UK
  Generation of a single-chain Fv with binding specificity for the integrin, αvβ6, by rational structure based antibody engineering – a promising agent for cancer therapy – Proffered Paper Presentation

- **Celine Cano-Soumillac**
  Northern Institute for Cancer Research, Newcastle upon Tyne, UK
  Structure-activity relationships for inhibitors of DNA-dependent protein kinase – Proffered Paper Presentation

**Wednesday 3 October 2007**
Basic biology of lung cancer
Hosted by Tim Eisen
University of Cambridge, UK

- **Tim Eisen**
  University of Cambridge, UK
  Introduction: blue sky research in a smoky disease

- **Pamela Rabbitts**
  Leeds Institute of Molecular Medicine, St James's University Hospital, UK
  Genetic abnormalities in lung tumour progression

- **Elisabeth Brambilla**
  University Hospital Albert Michallon, Grenoble, France
  Molecular pathological correlates in lung cancer

- **Thomas d'Amato**
  Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA
  Chemotherapy resistance testing in non-small cell lung cancer – integration into clinical trials

- **Martin Muers**
  Leeds General Infirmary, UK
  A randomised phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: The Medical Research Council (MRC) / British Thoracic Society (BTS) MS01 trial – Proffered Paper Presentation

- **Marianne Nicolson**
  Aberdeen Royal Hospitals Trust, UK
  Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): The MRC LU22 / NVALT 2 / EORTC 08012 multi-centre randomised trial – Proffered Paper Presentation

- **Nadia Ashraf**
  Gloucestershire Oncology Centre, Cheltenham General Hospital, UK
  RECIST guidelines overestimate the volumetric response of locally advanced Non-Small Cell Lung Cancer (NSCLC) to chemotherapy – Proffered Paper Presentation

Bioinformatics for cancer research
Hosted by Robin Clark
NCRI Informatics Initiative, London, UK

- **Robin Clark**
  NCRI Informatics Initiative, London, UK
  Introduction

- **Phil Quirke**
  St James's University Hospital, Leeds, UK
  Integration of cancer imaging and pathology

- **Ken Buetow**
  National Cancer Institute, Rockville, USA
  Enabling the molecular medicine revolution through network-centric biomedicine
o **Helen Byrne**  
University of Nottingham, UK  
Colorectal cancer in silico: a multiscale theoretical  

o **Elizabeth Ireland**  
Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, UK  
Has the Consolidated Standards of Reporting Trials (CONSORT) statement improved the publication quality of early breast cancer (EBC) randomised controlled trials (RCTs) in systemic treatment: a systematic review – Proffered Paper Presentation  

o **Clare Peckitt**  
The Institute of Cancer Research, Sutton, United Kingdom  
Defining endpoints for recurrence in randomised controlled trials of systemic therapy for early breast cancer: a call for standardisation – Proffered Paper Presentation  

o **Crispin Miller**  
Paterson Institute for Cancer Research, University of Manchester, UK  
Exploiting sample variability to enhance the analysis of microarray data – Proffered Paper Presentation  

---  

**Cancer in developing countries**  
Hosted by Maxwell Parkin  
University of Oxford, UK  

o **Maxwell Parkin**  
University of Oxford, UK  
Introduction: cancer in developing countries  

o **Cecilia Sepulveda**  
World Health Organisation, Geneva, Switzerland  
WHO strategies for cancer control in developing countries  

o **Rengaswamy Sankaranarayanan**  
International Agency for Research on Cancer, Lyon, France  
Early diagnosis and screening in developing countries  

o **Ian Magrath**  
International Network for Cancer Treatment and Research, Institute Pasteur, Brussels, Belgium  
Treatment of cancer in developing countries  

o **Valerie McCormack**  
London School of Hygiene and Tropical Medicine, UK  
Breast density in White, Afro-Caribbean and South Asian women in the UK – Proffered Paper Presentation  

o **Benjamart Warasiha**  
School of Pharmacy, The Robert Gordon University, Aberdeen, UK  
Comparative analysis of cytochrome P450 mRNA expression between human Caucasian and Afro-Caribbean breast cancer cell lines – Proffered Paper Presentation  

o **Sunita Saxena**  
Institute Of Pathology, Indian Council of Medical Research, New Delhi, India
Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis – Proffered Paper Presentation

Hosted by Stephen Shuttleworth

- **Kate Searle**

- **Sarah Lowndes**
  Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
  Phase I study of ATN-224 (choline tetrathiomolybdate) in metastatic cancer

- **Malcolm Ranson**
  Christie Hospital, University of Manchester, UK
  CR-UK Phase I trial of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7 or 3 days in patients with advanced refractory cancer

- **Shamim Kazmi-Stokes and Hayley Farmer**
  Preclinical development and safety strategy for regulatory approval of a Phase I trial of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4

- **Paul Jones**
  Non-clinical development activities at the CR-UK Drug Development Office

- **Caterina Macedo**
  Pharmacovigilance in CR-UK’s Drug Development Office

- **Stephen Shuttleworth**
  Initiatives for implementation of new clinical programmes

End of life care
Hosted by Julia Addington-Hall
School of Nursing and Midwifery, University of Southampton, UK

- **Julia Addington-Hall**
  School of Nursing and Midwifery, University of Southampton, UK
  Introduction: predictors of place of death

- **Luc Delliens**
  Vrije Universiteit, Brussels, Belgium and VU University Medical Center, Amsterdam, The Netherlands
Hospital deaths in six European countries: population-based cross national study of factors associated with dying in hospital

- **Barbara Gomes**  
  Weston Education Centre, King’s College London, UK  
  Home death in cancer: associated factors, future issues?

- **Carol Thomas**  
  Institute for Health Research, Lancaster University, UK  
  What can qualitative data add to knowledge about place of cancer deaths?

- **Peter Madden**  
  Thames Cancer Registry, King’s College, London, UK  
  Using maps, ranked bar charts and funnel plots to examine variation in place of death from cancer in London’s Primary Care Trusts – Proffered Paper Presentation

- **Simon Waters**  
  Medical Oncology, St James’ University Hospital, Leeds, UK  
  Patient mortality within thirty days of receiving systemic anti-cancer therapy: The Leeds experience – Proffered Paper Presentation

- **Jamie Young**  
  University of Dundee, Scotland, UK  
  In hospital deaths with and without a gastrointestinal cancer operation in Scotland over ten years – Proffered Paper Presentation

**Inflammation in cancer**  
Hosted by Claire Lewis  
University of Sheffield Medical School, UK

- **Claire Lewis**  
  University of Sheffield Medical School, UK  
  Introduction: the emerging role of inflammation in tumour progression

- **Michele de Palma**  
  Institute for Cancer Research and Treatment, Milan, Italy  
  Role of Tie2-expressing monocytes in cancer

- **Thorsten Hagemann**  
  Institute of Cancer and CR-UK Clinical Cancer Centre, Barts and The London, UK  
  ‘Re-educating’ tumour-associated macrophages

- **Karin de Visser**  
  Netherlands Cancer Institute, The Netherlands  
  Crosstalk between adaptive and innate immunity enhances epithelial cancer development

- **Russell Hughes**  
  University of Sheffield Tumour Targeting Group, South Yorkshire, UK  
  Necrotic debris activates a pro-tumour phenotype in human macrophages: role of the cell surface receptors, SR-A and TLR-2 – Proffered Paper Presentation
Kellie Charles
Institute of Cancer, London, UK
TNF-α antagonism inhibits inflammatory cytokine gene expression profile and NF-κB activity in the tumour microenvironment of patients with advanced ovarian epithelial cancer – Proffered Paper Presentation

Daniel Palmer
University of Birmingham, UK
CD40 ligand cancer immuno-gene therapy directly induces apoptosis in human carcinomas – Proffered Paper Presentation

Patients, research and involvement
Hosted by Roger Wilson and Nina Ennis
NCRI Consumer Liaison Group, UK

Nina Ennis
NCRI Consumer Liaison Group, UK
Introduction

Neil Formstone
Wales Cancer Bank, Royal College of Pathologists Lay Committee, and Macmillan Listening Study, UK
What is patient advocacy in research?

Raymond Strachan
Ceco Palliative Care Group, NCRN Palliative Care Group, Macmillan Cancer Support Research Group, Scottish Executive Cancer Group, Scottish Intercollegiate Guidelines Network and North of Scotland Cancer Group, UK
Research in Scotland: a service users input

Jim Elliott
Macmillan Cancer Support, UK
Title to be confirmed

Ikumi Okamoto
University of Southampton, UK
Impact of cancer on everyday life: a systematic appraisal of the research evidence – Proffered Paper Presentation

Julie Evans
University of Oxford, UK
Experiences of cancer on www.dipex.org: an award winning ‘innovative and humanistic’ resource – Proffered Paper Presentation

Prostate cancer
Hosted by Jonathan Shamash
St Bartholomew's Hospital, London, UK

Jonathan Shamash
St Bartholomew's Hospital, London, UK
Introduction

Johann de Bono
Hormone refractory prostate cancer may frequently remain ligand driven: inhibition of CYP17 by abiraterone

- **Norman Maitland**  
  University of York, UK  
  Prostate cancer stem cells: new therapeutic targets?

- **William Isaacs**  
  Johns Hopkins University, Baltimore, USA  
  Molecular genetics of prostate cancer - challenges and opportunities

- **Alison Reid**  
  Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Sutton, UK  
  Abiraterone, an oral, selective, irreversible inhibitor of CYP450c17, inhibits androgen and oestrogen synthesis and has activity in post-docetaxel castration resistant prostate cancer – Proffered Paper Presentation

- **Gerhardt Attard**  
  Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK  
  Inhibition of androgen synthesis by selective inhibition of CYP450c17 results in a high response rate in castration-resistant prostate cancer (CRPC) – Proffered Paper Presentation

- **Jacqueline Stockley**  
  Northern Institute for Cancer Research, Newcastle University, UK  
  Androgen ablation increases cellular resistance to taxane based chemotherapy in prostate cancer cells – Proffered Paper Presentation
Workshops

Sunday 30 September 2007

**AstraZeneca Science Symposium - Patient selection strategies in oncology: opportunities and challenges**

*Sponsored by AstraZeneca*

12.30 – 13.45

*Hosted by Stephen Wedge*  
AstraZeneca, Cheshire, UK

- **Stephen Wedge**  
  AstraZeneca, Cheshire, UK  
  Introduction

- **Alan Barge**  
  AstraZeneca, Cheshire, UK  
  Learning from the inhibition of EGFR signalling

- **Paul Smith**  
  AstraZeneca, Cheshire, UK  
  Understanding tumour dependencies on MEK signalling

- **Mark O’Connor**  
  KuDOS Pharmaceuticals Limited, Cambridge, UK  
  Targeted therapy based on DNA repair inhibition

**Molecular profiling in cancer**

*Sponsored by the Cancer Recognised Research Group in Northern Ireland*

13.00 – 15.00

*Hosted by Hendrik van den Berg and Charles Campbell*  
Queen’s University Belfast, Northern Ireland, UK

- **Carlos Caldas**  
  Department of Oncology, University of Cambridge, UK  
  Genomic heterogeneity of breast cancer - biological and clinical implications

- **Wendy Allen**  
  Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK  
  Identification of predictive signatures of response to chemotherapy in metastatic colorectal cancer

- **Niamh O’Brien**  
  Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK  
  The identification of transcriptional targets of TBX2 and their role in breast cancer proliferation

- **Glenda McGonigle**  
  Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, UK  
  Identification of HOXA6 as a novel candidate gene in AML
Seóna McErlean  
University of Ulster, Coleraine, Northern Ireland, UK  
The pathway to breast cancer invasion

**Thrombosis and malignancy workshop**  
13.00 – 15.00  
**Chaired by Mike Richards**  
National Cancer Research Institute, UK

- **Anita Thomas**  
  Derriford Hospital, Plymouth, UK  
The scale of the problem

- **Ajay Kakkar**  
  Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK  
Prophylaxis

- **Annie Young**  
  3 Counties Cancer Network, UK  
Treatment

- **Anthony Maraveyas**  
  Postgraduate Medical Institute, University of Hull, UK  
Current clinical trials: FRAGEM

- **Simon Noble**  
  Cardiff University, UK  
Current clinical trials: FRAGMATIC

- **Ajay Kakkar**  
  Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK  
Future clinical research

Monday 1 October 2007

**BACR educational workshop: RNAi technologies**  
08.00 – 08.50  
**Hosted by William Gallagher**  
University College Dublin, Ireland

- **Michael White**  
  University of Texas Southwestern Medical Center, Dallas, USA  
Discovery biology and RNAi

**BOA educational workshop: Clinical application of cancer genetics**  
08.00 – 08.50  
**Hosted by Ros Eeles**  
The Institute of Cancer Research, London, UK
Commercial workshop: Advances in hepatocellular carcinoma
Sponsored by Bayer Schering Pharma
13:00 - 14:00
Hosted by Jeffrey Evans
Centre for Oncology and Applied Pharmacology, University of Glasgow, UK
- Tim Meyer
  Royal Free Hospital, London, UK
  Future treatments of hepatocellular cancer
- Speaker to be confirmed
  Epidemiology staging and prognosis of hepatocellular cancer
- Speaker to be confirmed
  The management of hepatocellular cancer

Commercial workshop: Cancer DSA™ - a platform for discovery in oncogenomics
Sponsored by Almac Diagnostics
13:00 - 14:00
Hosted by Patrick Johnston
School of Biomedical Sciences, Queens University, Belfast, UK
- Karl Mulligan
  Almac Diagnostics, Craigavon, Northern Ireland, UK
  Deciphering the transcriptome: rationale for development and technical overview of the Cancer DSA™ range of research tools and their applications in basic, pre-clinical and clinical research
- Paul Mullan
  School of Biomedical Sciences, Queens University, Belfast, UK
  Identification of the novel functions of the proto-oncotype TBX2 that is over-expressed in 15-20% of breast cancer cases
- Lisa Baumbach-Reardon
  Dr John T MacDonald Foundation Centre for Medical Genetics, University of Miami, USA
  Multi-ethnic comparisons of genomic signatures in breast cancer using the Breast Cancer DSA™ research tool

Careers workshop for research nurses involved in clinical trials
14.00 – 15.00
Hosted by Anne Croudass
University of Southampton, UK

Clinical fellows’ careers workshop
14.00 – 15.00
Hosted by Simon Vincent
Cancer Research UK, London, UK
- Kiki Thahtis
  Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
Does pancreatic cancer get the attention it deserves? How can we improve survival rates in pancreatic cancer?
Sponsored by Pancreatic Cancer UK
14.00 – 15.00
Hosted by Sue Ballard
Pancreatic Cancer UK
Co-chaired by John Neoptolemos¹, Pippa Corrie² and Steve Pereira³
¹University of Liverpool, UK; ²Addenbrooke’s Hospital and University of Cambridge, UK; ³Pancreatic Society, BSG and University College London Hospital, UK

- Les Niewiara
  Pancreatic Cancer UK
  Cancer of the what? Striving for survival – the patient view

- Nick Lemoine
  Institute of Cancer and CR-UK Clinical Centre, University of London, UK
  Can the pancreas learn from other cancers or should they be learning from the pancreas? Can the pancreas achieve as high a profile as the breast?

- Ross Carter
  Pancreatic Society and Glasgow Royal Infirmary, UK
  The view from the coal-face: can we make it a properly equipped front-line?

- Sue Ballard
  Pancreatic Cancer UK
  Final comment

Post doc's careers workshop
14.00 – 15.00

- Sarah Loddick
  AstraZeneca, UK

- Peter Burdon
  Novartis, UK

- Richard Kennedy
  Almac Diagnostics, UK

- Isobel Greenfield
  Roche, UK

BACR Prize Lectures: BACR/AstraZeneca Young Scientist Frank Rose Award and BACR Translational Research Award
14.00 – 15.00
Hosted by Robert Brown
Chairman of the BACR, UK

- Owen Sansom
  Beatson Institute for Cancer Research, Glasgow, UK
  C-myc deficiency rescues APC deficiency, prevents Wnt dependent intestinal regeneration and is required for the DNA damage response in vivo

- Jorge Reis-Filho
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

Basal-like carcinomas: from pathology to mouse-models and beyond

Tuesday 2 October 2007

BACR educational workshop: Therapeutic approaches to targeting tumour apoptosis - How basic pathway analysis has led to new drugs
08.00 – 08.50
Hosted by Caroline Dive
Paterson Institute for Cancer Research, University of Manchester, UK

- **Sarah Holt**
  Paterson Institute for Cancer Research, University of Manchester, UK
  Understanding the regulation of apoptosis

- **Caroline Dive**
  Paterson Institute for Cancer Research, University of Manchester, UK
  Therapeutic attack on apoptosis pathways

BOA educational workshop: Clinical role of advanced technology in radiation therapy
08.00 – 08.50
Hosted by Christopher Nutting
Royal Marsden Hospital and The Institute of Cancer Research, London, UK

- **Christopher Nutting**
  Royal Marsden Hospital and The Institute of Cancer Research, London, UK
  Advances in technology in radiation therapy

- **Ranald MacKay**
  Christie Hospital, Manchester, UK
  The impact of image guidance in radiotherapy

Commercial workshop: Integrated microarray based approaches to cancer genomics
Sponsored by Affymetrix
13.00 – 14.00
Hosted by Ruby Gadelrab
Marketing Programs, Affymetrix

- **Pim French**
  Erasmus MC, Rotterdam, The Netherlands
  Identification of molecular subgroups and genetic aberrations in glial brain tumours

- **Geoff Scopes**
  Affymetrix, UK
Integrated approaches in cancer research - Increasing the value of a cancer genome study

Commercial workshop: Delivering tomorrow’s cancer drugs: Sanofi-Aventis oncology pipeline and late stage trials
Sponsored by Sanofi-Aventis
13.00 – 14.00
Hosted by Isabelle Tabah-Fiche
Global Oncology Franchise, Sanofi-Aventis, UK
  o Isabelle Tabah-Fiche
    Global Oncology Franchise, Sanofi-Aventis, UK
    Delivering tomorrow's cancer drugs: Sanofi-Aventis oncology pipeline

How to publish your results
Sponsored by the British Journal of Cancer
14.00 – 15.00
Hosted by Nicola McCarthy
Nature Reviews Cancer, UK

Designing a clinical trial - from inspirational idea to grant application
14.00 – 15.00
Hosted by Judith Bliss
The Institute of Cancer Research, Sutton, UK
  o Andrew Tutt
    Breakthrough Research Centre, London, and Guy's, Kings and St Thomas' Cancer Centre, London, UK
  o Lindsay Johnson
    The Institute of Cancer Research, Sutton, UK
  o Jo Haviland
    The Institute of Cancer Research, Sutton, UK

PhD students’ careers workshop: how to find a post doc position
14.00 – 15.00
Hosted by Sally Leevers
CR-UK London Research Institute, UK
  o Sheila Bingham
    MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, University of Cambridge, UK
  o Carl-Henrik Heldin
    Ludwig Institute for Cancer Research, Uppsala University, Sweden
  o Tony Kouzarides
    Wellcome Trust/CR-UK Gurdon Institute, University of Cambridge, UK
Women in science workshop – Addressing the problems
14.00 – 15.00
Hosted by Clare Isacke
Breakthrough Breast Cancer Research Centre, UK
  o Rebecca Smith
    Biochemical Society, UK

Wednesday 3 October 2007

Commercial workshop: Epigenetics and regulatory analysis in the cancer genome: applications of Chromatin IP (ChIP) and MeDIP
Sponsored by Affymetrix
13.00 – 17.00
Hosted by Geoff Scopes
Affymetrix Ltd, UK
  o Geoff Scopes
    Affymetrix Ltd, UK
    Welcome and introduction
  o Jason Carroll
    CR-UK Cambridge Research Institute, UK
    Whole genome oestrogen receptor binding
  o Jason Carroll, Alex Watkins and Geoff Scopes
    CR-UK Cambridge Research Institute and Affymetrix Ltd, UK
    Panel-led interactive discussion session: considerations for ChIP-on-chip experimental design
  o Alex Watkins
    Affymetrix Ltd, UK
    Data analysis session introduction: TAS and IGB
  o Speaker to be announced
    Affymetrix Ltd, UK
    Genome Suite from Partek for ChIP-on-chip analysis
  o Martin Seifert
    Genomatix, UK
    Genomatix ChIPInspector
  o Geoff Scopes
    Affymetrix Ltd, UK
    Discussion - Data analysis and other questions